Autolus Therapeutics vs Immunocore
AUTL and IMCR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AUTL and IMCR compare
Immunocore is the larger company, worth 5.0 times as much as Autolus Therapeutics ($1.5B against $311M).
Autolus Therapeutics grew revenue faster over the last twelve months (169% versus 13.1% for Immunocore).
Immunocore keeps more of each dollar of sales as profit, with a net margin of −7.5% compared with −186% at Autolus Therapeutics.
Immunocore scores higher on the StockData Score (7 against 4 for Autolus Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AUTL | IMCR |
|---|---|---|
| Size and price | ||
| Market cap | $311M | $1.5B |
| Share price | $1.17 | $29.94 |
| Change, 1 year | −14.0% | −15.2% |
| Change, 5 years | −81.2% | −21.4% |
| Beta (5Y) | 1.84 | 0.69 |
| Employees | 754 | 524 |
| StockData Score | ||
| Total score | 4 | 7 (better) |
| Valuation score | 0 | 1 (better) |
| Growth score | 3 (better) | 2 |
| Performance score | 0 | 3 (better) |
| Health score | 1 | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.3× (better) | 3.6× |
| P/B | 11.4× | 3.7× (better) |
| FCF yield | −57.9% | −1.2% (better) |
| Fair value | – | $31.07 |
| Margin of safety | – | 3.6% |
| Growth | ||
| Revenue growth (TTM) | 169% (better) | 13.1% |
| Profitability | ||
| Gross margin | 35.8% | 98.9% (better) |
| Operating margin | −160% | −6.8% (better) |
| Net margin | −186% | −7.5% (better) |
| FCF margin | −131% | −4.2% (better) |
| Return on equity | −175% | −7.9% (better) |
| Financial health | ||
| Interest coverage | −4.8× | −2.4× (better) |
| Current ratio | 3.72 | 4.62 (better) |
| Altman Z-score | −4.28 | 1.45 (better) |
| Piotroski F-score | 2 | 3 (better) |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 49.7% | 102% |
| Held by insiders | 24.6% | 15.5% |
| Insider net buying, 12 months | −$15.7K (better) | −$1.9M |
Go deeper
- AUTL stock overview
- AUTL income statement
- AUTL valuation and score
- IMCR stock overview
- IMCR income statement
- IMCR valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.